OBJECTIVE: Fibroblast growth factors (FGFs) and their receptors (FGFRs) play important roles in the vascular system. The FGFR4 rs351855 (Gly388Arg) poly morphism has been shown to be a risk factor for many diseases.
Introduction
Ischaemic stroke is one of the most complex disorders and has diverse causes. Age, hypertension, diabetes mellitus, smoking, hyperlipidaemia and cardiac disease are well established risk factors, but one-third of stroke patients have no confirmed aetiology. 1 Genetic and environmental backgrounds probably play roles in the pathogenesis of ischaemic stroke.
Fibroblast growth factor (FGF)-1 and FGF-2 are pleiotropic growth factors that exert a broad spectrum of biological activities on the cell types responsible for human atheromata and restenosis following angioplasty. 2 For example, in vitro, FGF-1 and FGF-2 promote smooth muscle cell proliferation, migration and proteoglycan synthesis 3, 4 and exhibit potent angiogenic activity towards endothelial cells. 5 Both FGF-1 and FGF-2 are synthesized by macrophages, endothelial cells and vascular smooth muscle cells in culture, 3, 6, 7 and have been localized to these cell types in human atherosclerotic arteries. 8 HF Zhang, KJ Zhao, PF Yang et al.
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This suggests that aberrant FGF activity may be involved in human atherogenesis: a hypothesis that is reinforced by studies on animal model systems of experimental arterial injury. In the rat balloon catheter injury model, exogenous FGF-2 stimulates intimal hyperplasia, 9 and both FGF-1 and FGF-2 promote endothelial repair. 10, 11 The induction of FGF receptor 1 (FGFR1) in medial smooth muscle cells in this model system further supports a role for FGFs in the pathology of restenosis following balloon angioplasty. 12, 13 Moreover, immunolocalization research has demonstrated FGF2 gene expression in the intimal microvasculature of complicated plaques and in microvessels recanalizing organizing thrombi, which provides circumstantial evidence of the role of FGF-2 in the pathophysiological regulation of new vessel growth in the plaque. 8 Similarly, application of exogenous FGF-2 to the adventitia of the rat carotid artery promotes vascularization of the vasa vasorum, 14 and secreted FGF-1 in the porcine arterial wall induces neovascularization and hyperplasia of the arterial intima. 15 FGF-1 and FGF-2 mediate their biological effects by binding to (and activating) a family of specific high-affinity cell surface FGF receptors (FGFR)1 -4, which have protein tyrosine kinase activity. Research indicates that the FGF-FGFR system is crucial in providing vascular protection. 10 -15 The FGFR1 -4 genes are expressed differentially in each tissue or cell type and have distinct differences in their receptor functions. 16 -19 A germ-line polymorphism in the FGFR4 gene, resulting in the expression of FGFR4 containing either glycine (Gly388) or arginine (Arg388) at codon 388, was identified several years ago, 20 and the presence of the FGFR4 Arg388 allele causes increased receptor stability and sustained receptor activation. 21 This polymorphism has been shown to be associated with different diseases including prostate cancer and breast cancer. 21, 22 In addition, the Gly388Arg polymorphism is reported to be associated with coronary artery disease. 23 The present study investigated the possible association between the FGFR4 Gly388Arg polymorphism and ischaemic stroke.
Patients and methods

STUDY POPULATION
Chinese patients hospitalized for a first nonfatal ischaemic stroke and control subjects (outpatients without a history of stroke who were attending the hospital for a general health examination) were recruited sequentially from Changhai Hospital, Second Military Medical University, Shanghai, China, between January 2009 and May 2011. All controls were matched with patients for age, sex and residence area (urban or rural). Patients with cardioembolic strokes, or strokes of undetermined or unknown origin, were excluded from this study to make the study population more homogeneous. Brain computed tomography and/or brain magnetic resonance imaging, and electrocardiography, were performed in all patients. Participants who reported that they were related to other participants were excluded from the study. Individuals with a history of stroke, Alzheimer's disease, brain aneurysm, dementia, dystonia or Parkinson's disease were excluded from the control group.
Written informed consent was obtained from each participant. The study was approved by the Review Board of Changhai Hospital.
GENETIC ANALYSES
Genomic DNA was extracted from peripheral blood using a commercially 
STATISTICAL ANALYSES
Statistical analyses were carried out using the SPSS ® statistical software package, version 13.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . The deviation of genotypes from Hardy-Weinberg equilibrium was tested by comparing observed and expected genotype frequencies, using the χ 2 -test. For the analysis of single-nucleotide polymorphisms (SNPs), genotype and allele frequencies were compared between groups using the χ 2 -test, and odds ratios (OR) and 95% confidence intervals (CIs) were calculated using unconditional logistic regression. A P-value < 0.05 was considered to be statistically significant.
Results
The study group included 952 patients with ischaemic stroke and 986 healthy controls. The clinical characteristics of all participants are shown in Table 1 . Age and gender did not differ significantly between the stroke patients and healthy controls. As expected, when compared with the control group, the ischaemic stroke group had significantly higher mean body mass index, percentages of smokers and alcohol drinkers, and percentages of patients with hypertension and diabetes (P < 0.001 for all comparisons).
The frequency of the FGFR4 rs351855G/A (Gly388Arg) polymorphism is shown in Table 2 . Genotypes GG, GA and AA were identified in both groups. All the SNPs genotyped were in Hardy-Weinberg equilibrium. The frequencies of the GA and AA genotypes, and of the A allele, were all significantly lower in stroke patients than in controls ( Table 2) .
Associations between the FGFR4 polymorphism and clinical parameters in stroke patients are shown in Table 3 . Genotype and allele frequencies did not differ between the sexes, or between patients with or without hypertension. Stroke patients with diabetes had significantly higher frequencies of genotype AA and allele A compared with controls.
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Discussion
The rs351855G/A (Gly388Arg) polymorphism of the FGFR4 gene was identified several years ago. 20 Research has generally focused on its relationship with various cancers, showing that rs351855A (388Arg) can be a risk factor for cancers such as prostate and breast cancer. 21, 22 Findings of the present study suggest that genotype AA and allele A of the FGFR4 rs351855G/A polymorphism are associated with decreased susceptibility to ischaemic stroke in the Chinese population, and that the FGFR4 polymorphism can act as a protective factor against ischaemic stroke. These findings therefore indicate that a single polymorphism may have diverse functions in different diseases.
Human genetic polymorphisms may be associated with various diseases. 23 -26 The FGFR4
rs351855 polymorphism was investigated in the Chinese population in the HF Zhang, KJ Zhao, PF Yang et al. FGFR polymorphism and ischaemic stroke present study. The frequency of the A allele in the control group was 41.5%, which is consistent with other studies. 27 Because of the higher frequency of this allele (Arg388) in Asian populations than in Caucasians, 28 analysis of the FGFR4 polymorphism may benefit from higher statistical power in Asians than in Caucasians. It would be interesting to investigate this polymorphism and ischaemic stroke in different ethnic populations.
The four closely related human FGFRs and their > 20 known ligands control a multitude of cellular processes including cell growth, differentiation and migration, and it has been shown that the FGF-FGFR system plays a critical role in cancer development because is has the potential to induce angiogenesis, which may directly enhance tumour growth. 29 For example, autocrine growth stimulation through the coexpression of FGF and FGFR in the same cell results in the transformation of BALB/c 3T3 cells. 30 A high level of FGFR4 expression has been found in pancreatic, breast and renal cell carcinomas. 31 -34 The FGF-FGFR system is also important in the pathology of human atherosclerosis, 8 and the Gly388Arg polymorphism has been associated with coronary artery disease. 23 Thus, we hypothesized that the Gly388Arg polymorphism may affect ischaemic stroke. The frequency of Arg388 was significantly lower in stroke patients than in healthy controls in the Chinese population. The mechanism by which the Gly388Arg polymorphism induces diverse processes in different diseases remains unclear, however. It has been shown that the presence of the FGFR4 Arg388 allele causes increased receptor stability and sustained receptor activation. 21 Thus, it may promote tumorigenesis, including the upregulation of proliferation, motility and angiogenesis; alternatively, it may increase the effects of FGF-1 and FGF-2 on vascular smooth muscle cell proliferation and, therefore, influence the development of atherosclerosis. 35 The present study also demonstrated that the Gly388Arg polymorphism is associated with increased incidence in patients with diabetes, which suggests that the polymorphism may also affect the development of diabetes. Further study in this field is needed.
In conclusion, the present case-control study revealed that the FGFR4 rs351855G/A (Gly388Arg) polymorphism is associated with decreased risk of stroke in the Chinese population. This raises the possibility that a function shift caused by genetic variants could have important consequences for the pathogenesis of ischaemic stroke.
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